The Department of Health and Human Services has pulled a controversial proposed rule on drug discounts for safety-net providers such as hospitals, which was under review at the White House, according to Bloomberg BNA’s Bronwyn Mixter.
Martin Kramer, director of communications at the HHS Health Resources and Services Administration said the agency in 2015 “plans to issue a proposed guidance for notice and comment that will address key policy issues raised by various stakeholders committed to the integrity of the 340B program. HRSA is also planning to issue proposed regulations where the statute provides explicit rulemaking authority, pertaining to civil monetary penalties for manufacturers, calculation of the 340B ceiling price, and administrative dispute resolution.”
The 340B program requires drug manufacturers to provide discounts or rebates to certain hospitals that serve a disproportionate share of low-income patients. Pharmaceutical companies and safety net providers have been at odds over the rule. Hospitals have argued the program helps them better serve vulnerable patients. But drug makers say HRSA’s interpretation of the 340B orphan drug exemption, enacted as part of the Affordable Care Act, significantly expanded the type of entities that can access previous 340 discounts for prescription drugs.
The decision to withdraw the regulation wasn't surprising and may have been partially motivated by the recent election, an attorney told Bloomberg BNA Nov. 14.
Attorney Donna Lee Yesner of Morgan, Lewis & Bockius LLP in Washington said the election may “partially explain” the decision because issuing the proposed rule might have triggered “unwanted oversight from the Republican-controlled Congress.”
Take a free trial the Health Law Resource Center to receive industry-leading health law news and analysis.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)